API manufacturer Olon acquires Infa Group
Acquisition expected to double the Italian manufacturer's generics portfolio.
P&R and Infa Group shareholders have reached the deal closing for the transaction of 100% Infa shares to Olon SpA.
Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide, for both generics and contract manufacturing.
Olon owns five manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees, whereas Infa Group, with more than 400 employees, has two manufacturing sites in Italy (Labochim and Sifavitor) and one in Spain (Derivados Químicos).
The acquisition will broaden and diversify the portfolio by doubling it to more than 200 generic products and will strengthen its CDMO business.
Olon's 2015 revenue was above €200 million. The 2016 total pro-forma revenue, combining Olon and Infa, is expected to exceed €300 million, confirming the birth of a significant player in Europe, as well as in the US.
"The acquisition of Infa will provide an established custom synthesis presence with customers worldwide and will strengthen our generic position by adding a large amount of products positioning Olon as one of the largest player in Europe," said Paolo Tubertini, Olon CEO.
Strategic advantages of the acquisition
The merger of Olon and Infa will expand Olon's products portfolio, which already includes fermented and semi-synthetic APIs, HPAPIs and cytotoxic compounds, controlled substances, retinoids, antivirals, biologics and recombinant peptides.
Olon and Infa will have available about 130 Active US Drug Master Files (DMFs) and more than 50 EU Certificates of Suitability (COS) or Compliance with the European Pharmacopoeia (CEP) and will rely on eight manufacturing facilities self-identified under GDUFA.
The acquisition will strengthen its services to CDMO customers from early clinical phases up to the commercial manufacturing.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance